Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.205
-0.015 (-1.23%)
At close: Jul 24, 2026, 4:00 PM EDT
1.200
-0.005 (-0.41%)
After-hours: Jul 24, 2026, 7:11 PM EDT

Metagenomi Therapeutics Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Metagenomi Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $7.67. The average 1-year stock price forecast is 536.51% higher than the current stock price, while the lowest is $5.00 (+314.94%) and the highest is $9.00 (+646.89%).

Price Target: $7.67 (+536.51%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$5.00$7.67$9.00$9.00
Change+314.94%+536.51%+646.89%+646.89%

Analyst Ratings

The average analyst rating for Metagenomi Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJan '26Feb '26Mar '26Apr '26May '26Jul '26
Strong Buy444434
Buy000000
Hold111111
Sell000000
Strong Sell000000
Total555545

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Chardan Capital
Chardan Capital
Buy
Maintains
$5
BuyMaintains$5+314.94%Jul 7, 2026
Wells Fargo
Wells Fargo
Buy
Maintains
$12$9
BuyMaintains$12$9+646.89%May 12, 2026
TD Cowen
TD Cowen
Buy
Maintains
n/a
BuyMaintainsn/an/aMay 11, 2026

Financial Forecast

Revenue This Year
10.25M
from 25.21M
Decreased by -59.35%
Revenue Next Year
11.15M
from 10.25M
Increased by 8.84%
EPS This Year
-2.16
from -2.36
EPS Next Year
-2.12
from -2.16
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
243.00K17.20M44.76M52.30M25.21M10.25M
Revenue Growth
-6,978.19%160.21%16.85%-51.79%-59.35%
Operating Income
-23.95M-44.64M-78.49M-88.90M-96.01M-92.34M
Net Income
-21.44M-43.59M-68.26M-78.06M-87.87M-86.71M
EPS
-----2.36-2.16
Free Cash Flow
--19.71M-31.65M-73.35M-53.31M-78.00M
No. Analysts
-----5
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High16.2M
Avg10.2M
Low5.0M

Revenue Growth

Revenue Growth202620272028
High
-35.7%
Avg
-59.3%
Low
-80.2%

EPS Forecast

EPS202620272028
High-2.03
Avg-2.16
Low-2.24

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-